CCS1477 in patients

CellCentric’s first-in-class p300/CBP inhibitor is in patients with advanced, drug-resistant prostate cancer, as well as in patients with certain haematological malignancies

Patient enrolment

Potential suitability for enrolment in a CCS1477 clinical trial will be made by oncologists at our participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.

Study 01: Late stage prostate cancer

A Phase 1b/2a clinical trial is underway with Prof Johann de Bono, ICR/Royal Marsden Hospital, as Chief Investigator. Other sites are following in the UK including Belfast and Newcastle before expansion to the US including the Kimmel Cancer Center, TJU Philadelphia.

The initial phase is an incremental dose escalation exploring CCS1477 on its own, testing tolerability, biological effects and optimal dosing schedules. This will be followed by expansion into defined cohorts of patients, with CCS1477 being admistered on its own or in combination with one of either Xtandi (enzalutamide) or Zytiga (abiraterone).

If CCS1477 successfully progresses through clinical trials, over 80,000 patients annually, who are or become resistant to, second generation anti-hormonal drugs, could potentially benefit from being treated with CellCentric’s novel drug.

In addition, within clinical study 01, there is the ability to test CCS1477 in the dose expansion phase in patients with tumours with specific p300 or CBP gene mutations (bladder, lung cancer).

Study 02: Haematological cancers

A Phase 1b/2a multi-centre, multi-part study is evaluating CCS1477 as a monotherapy in patients with multiple myeloma, acute myeloid leukaemia (AML) and Non-Hodgkin Lymphoma (NHL).

As with the prostate study, once a monotherapy dose and schedule is established, CCS1477 will be trialled with existing agents, such as in combination with Pomalidomide for multiple myeloma.

Particularly in later stages, these diseases continue to have significant need of new treatments. It is estimated that over 20,000 patients could ultimately benefit from targeted treatment CCS1477.